Sat, May 30, 2026
[Archive]
Volume 18, Issue 1 (March-2026 2026)
Iranian Journal of Blood and Cancer 2026, 18(1): 26-39 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Singh P, Papatrick S, Singh V. Current Challenges and Neoantigen-Based Therapy for Glioblastoma Treatment. Iranian Journal of Blood and Cancer 2026; 18 (1) :26-39
URL: http://ijbc.ir/article-1-1857-en.html
URL: http://ijbc.ir/article-1-1857-en.html
1- Teerthanker Mahaveer Medical College and Research Centre, Teerthanker Mahaveer University, Moradabad, UP, India. , singhmatrejaprithpal@gmail.com
2- Teerthanker Mahaveer Medical College and Research Centre, Teerthanker Mahaveer University, Moradabad, UP, India.
2- Teerthanker Mahaveer Medical College and Research Centre, Teerthanker Mahaveer University, Moradabad, UP, India.
Abstract: (61 Views)
Despite common therapies including chemotherapy, surgery, and radiation, glioblastoma (GBM), the most aggressive, challenging, and resistant primary brain metastasis version, has a terrible prognosis when it comes to the survival chances. Although immunotherapy has demonstrated promise in treating a number of malignancies, its effectiveness in GBM is still restricted because of the tumor's extremely immunosuppressive microenvironment. Neoantigen-based treatments target tumor-specific antigens produced by somatic mutations, providing a unique and customized approach. Because tumor cells express these neoantigens exclusively, they are prime candidates for immune identification with the least amount of off-target consequences. Early clinical trials have shown the safety and immunogenicity of strategies like customized cancer vaccines and adoptive cell treatments (ACT). This review explores the potential of neoantigen-based immunotherapy in GBM, highlighting recent advancements, challenges, and future directions for improving treatment efficacy and patient outcomes.
: Review Article |
Subject:
Radiotherapy
Received: 2025/12/26 | Accepted: 2026/03/7 | Published: 2026/03/30
Received: 2025/12/26 | Accepted: 2026/03/7 | Published: 2026/03/30
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
- Iranian Journal of Blood and Cancer
- Journal Tel: +989369936116
- Publisher Tel: +982122275917
- Mail: Info@ijbc.ir
